Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
ALSA Ventures is a London-based venture capital firm founded to capitalize on European innovation in life sciences. The firm focuses on biotechnology companies developing novel therapeutics and operates primarily in Europe and the UK. Their investment strategy spans pre-seed to growth equity stages, leveraging a strong network within the biotechnology sector.
ALSA Ventures invests in biotechnology companies that are developing novel drugs and modalities across various disease areas. Their focus includes therapeutics for chronic inflammatory diseases, oncology, and gene therapies. Investment sizes and specific check amounts are not disclosed, but they participate throughout the drug development spectrum, from company formation to syndicate participation.
Notable companies in ALSA Ventures' portfolio include Axovia Therapeutics, which is developing the first gene therapy for diseases caused by cilia dysfunction; Vantage Biosciences, focused on addressing vision loss associated with diabetes; and Promatix, utilizing multi-omic insights to create next-generation cancer therapeutics.
Submit your pitch through their website's contact form for consideration.
Yes, ALSA Ventures often leads investment rounds, particularly in early-stage biotechnology companies.
ALSA Ventures is open to follow-on investments, supporting their portfolio companies through various stages of development.
The specific size of ALSA Ventures' current fund is not publicly disclosed, but they actively invest across multiple stages in the biotech sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.